1. Home
  2. GNPX vs SPHL Comparison

GNPX vs SPHL Comparison

Compare GNPX & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • SPHL
  • Stock Information
  • Founded
  • GNPX 2009
  • SPHL 2002
  • Country
  • GNPX United States
  • SPHL Singapore
  • Employees
  • GNPX N/A
  • SPHL N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • SPHL Homebuilding
  • Sector
  • GNPX Health Care
  • SPHL Consumer Discretionary
  • Exchange
  • GNPX Nasdaq
  • SPHL Nasdaq
  • Market Cap
  • GNPX 5.5M
  • SPHL 4.9M
  • IPO Year
  • GNPX 2018
  • SPHL 2024
  • Fundamental
  • Price
  • GNPX $0.25
  • SPHL $0.49
  • Analyst Decision
  • GNPX
  • SPHL
  • Analyst Count
  • GNPX 0
  • SPHL 0
  • Target Price
  • GNPX N/A
  • SPHL N/A
  • AVG Volume (30 Days)
  • GNPX 24.1M
  • SPHL 2.8M
  • Earning Date
  • GNPX 11-12-2025
  • SPHL 01-01-0001
  • Dividend Yield
  • GNPX N/A
  • SPHL N/A
  • EPS Growth
  • GNPX N/A
  • SPHL N/A
  • EPS
  • GNPX N/A
  • SPHL N/A
  • Revenue
  • GNPX N/A
  • SPHL $6,456,601.00
  • Revenue This Year
  • GNPX N/A
  • SPHL N/A
  • Revenue Next Year
  • GNPX N/A
  • SPHL N/A
  • P/E Ratio
  • GNPX N/A
  • SPHL N/A
  • Revenue Growth
  • GNPX N/A
  • SPHL N/A
  • 52 Week Low
  • GNPX $0.14
  • SPHL $0.35
  • 52 Week High
  • GNPX $3.97
  • SPHL $7.80
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 55.11
  • SPHL 48.68
  • Support Level
  • GNPX $0.22
  • SPHL $0.44
  • Resistance Level
  • GNPX $0.32
  • SPHL $0.87
  • Average True Range (ATR)
  • GNPX 0.05
  • SPHL 0.08
  • MACD
  • GNPX 0.01
  • SPHL 0.01
  • Stochastic Oscillator
  • GNPX 39.89
  • SPHL 20.84

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.

Share on Social Networks: